CTI BioPharma Corp. (NASDAQ:CTIC)

CAPS Rating: 1 out of 5

The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.


Player Avatar zzlangerhans (99.85) Submitted: 1/3/2013 2:26:21 AM : Outperform Start Price: $1.29 CTIC Score: +12.86

I've heard that a foolish consistency is the hobgoblin of little minds, so I've decided to expand my mind by greenthumbing Cell Therapeutics for the first time. Now, before even remotely thinking that I'm supporting this company, please read this link http://seekingalpha.com/article/1070571-ctic-strong-sell-therapeutics . It's the most awesome bash of a company and a CEO that I've ever read, and so richly deserved. I'm surprised there weren't photos of the diapers that Jim Bianco fouled in his infancy. And for good measure, read this http://www.thestreet.com/story/11786505/1/the-worst-biotech-ceo-of-2012-is.html?

Keep in mind also that when it comes to Cell Therapeutics, shareholders NEVER win. There's just too much money flowing into the pockets of the CEO too fast through too many channels. Bianco has undoubtedly pocketed tens of millions of shareholder dollars over the years. God only knows what the "real" market cap of this stock is with multiple series of preferred stock floating around.

If it isn't clear by now, this is a risky and experimental CAPS-only play to grab a few points on a possible rebound as management froths up the launch of spurious lymphoma chemo Pixuvri in Europe and a phase III trial of pacritinib in myelofibrosis. If I'm wrong, I get swirled into the next dilution and reverse split and lose my chance for Cell Therapeutics score supremacy forever. Que sera sera.

Featured Broker Partners